Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
One quick online search or scroll through social media and you'll find an endless amount of weight loss advice. But it's hard ...
A new study breaks down exactly how to stop eating ultra-processed foods in eight weeks. Here's what it found and what ...
Fenugreek seeds can help you a lot in reducing obesity and belly fat. Fenugreek seeds have anti inflammatory properties that can help improve overall health. They speed up metabolism and reduce belly ...
The Healthy @Reader's Digest on MSN2d
How Much Weight Can You Lose in a Month? A Cleveland Clinic Obesity Doctor Reveals an Optimally Healthy GoalAn expert Cleveland Clinic doctor reveals how much weight you can safely lose in a month and strategies to help you achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback